Evommune
Company Snapshot
Evommune is a clinical-stage biotechnology company focused on developing innovative therapies aimed at chronic inflammatory diseases. The company is advancing a portfolio of differentiated product candidates, with a primary focus on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Their mission is to improve patients' quality of life by addressing the limitations of existing therapies and providing rapid symptom relief and durable disease resolution.
Key Financials
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $7M | $5M | Not provided |
| YoY Growth | +40.0% | - | - |
| Adjusted Net Loss | -$66.8M | -$34.1M | Not provided |
| Margin % | -954.3% | -682.0% | - |
S-1 Highlights
Market & Competition
The company operates in the biotechnology market and competes with established players like Amgen, AbbVie, and Regeneron Pharmaceuticals. The market for chronic inflammatory diseases is significant, with a substantial impact on healthcare costs and patient quality of life.
Use of Proceeds
Evommune intends to use the proceeds from the IPO to fund clinical development of its product candidates, advance preclinical programs, and for general corporate purposes.
Key Risk Factors
- ●The company has incurred significant operating losses since inception and may never achieve profitability.
- ●There is substantial doubt about the company's ability to continue as a going concern due to its reliance on equity financing and recurring losses.
Reported Broker Availability
Reported by users or publicly disclosed. Information is for reference only.